<DOC>
	<DOC>NCT00886782</DOC>
	<brief_summary>The purpose of this study is to determine safety, tolerability and maximum tolerated dose of BMS-863233 in subjects advanced and/or Metastatic solid tumors.</brief_summary>
	<brief_title>A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Phase 1 Subjects with advanced and/or metastatic solid tumors who are either refractory to or have relapsed from standard therapies, or for whom a standard therapy does not exist. ECOG performance status ≤ 2 Accessible for treatment, PK sample collection and required study followup Total Bilirubin ≤ 1.5 x ULN and ALT, AST ≤ 2.5 x ULN Women who are pregnant or breastfeeding Subjects with known or suspected brain metastasis, primary brain tumors, or brain as the only site of disease Exposure to any investigational agent within 4 weeks of study drug administration Subjects a history of gastrointestinal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Advanced and/or Metastatic solid cancers</keyword>
</DOC>